Author

P. Workman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Pharmacology & Toxicology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Research Focus:drug response / drug discovery· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:chromatin & epigenetic regulation· 2 Assay:proteomics· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1

Frequent Co-Authors

P. A. Clarke· 5 shared B. Al-Lazikani· 3 shared C. Zhang· 3 shared A. A. Antolin· 2 shared A. Hervieu· 2 shared M. P. Licciardello· 2 shared A. De Haven Brandon· 1 shared A. Hayes· 1 shared

Activity by Year

2019-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

P. A. Clarke

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

R-loop editing by DNA cytosine deaminase APOBEC3B determines the activity of estrogen receptor enhancers

C. Zhang, Y.-j. LU, B. Chen, Z. Bai, A. Hervieu, M. P. Licciardello, M. Wang, K. Mitsopoulos, B. P. Al-Lazikani, M. Tortorici, O. Rossanese, P. Workman, P. A. Clarke

This study shows APOBEC3B edits R-loops at ER enhancers, leading to DSBs that contribute to genomic instability in breast cancer.

bioRxiv · Oct 21, 2022 · PreprintCancer Biology

Loss of Spindly sensitizes EML4-ALK v3 lung cancer cells to HSP90 inhibitors

M. P. Licciardello, C. Zhang, A. T. Le, R. C. Doebele, P. A. Clarke, P. Workman

The paper shows that loss of Spindly increases sensitivity of EML4-ALK v3 NSCLC cells to HSP90 inhibitors, but not v1 cells.

bioRxiv · Jun 8, 2022 · PreprintCancer Biology

Native size exclusion chromatography-based mass spectrometry (SEC-MS) identifies novel components of the Heat Shock Protein 90-dependent proteome

R. S. Samant, S. Batista, M. Larance, B. Ozer, C. I. Milton, I. Bludau, L. Biggins, S. Andrews, A. Hervieu, H. E. Johnston, B. Al-Lazikhani, A. I. Lamond, P. A. Clarke, P. Workman

This study uses SEC-MS to analyze HSP90 inhibitor effects on protein complexes, identifying both known and novel components of the HSP90-dependent proteome.

bioRxiv · May 23, 2022Biochemistry

Evolution of kinase polypharmacology across HSP90 drug discovery

A. A. Antolin, P. A. Clarke, I. Collins, P. Workman, B. Al-Lazikani

This study systematically characterizes the kinase cross-pharmacology of HSP90 inhibitors and shows that polypharmacology evolved during drug optimization.

bioRxiv · Sep 9, 2020Pharmacology & Toxicology

Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases

C. Zhang, S. R. Stockwell, M. Elbanna, R. Ketteler, J. Freeman, B. Al-Lazikani, S. Eccles, A. De Haven Brandon, F. Raynaud, A. Hayes, P. A. Clarke, P. Workman, S. Mittnacht

This study shows that MET/FAK signaling can activate CDK2 independently of CDK4/6, leading to cell division, and suggests targeting MET/FAK could enhance CDK4/6 inhibitor therapies.

bioRxiv · Apr 8, 2019Cancer Biology

The off-target kinase landscape of clinical PARP inhibitors

A. A. Antolin, M. Ameratunga, U. Banerji, P. Clarke, P. Workman, B. Al-Lazikani

This study identifies the off-target kinase profiles of four FDA-approved PARP inhibitors, revealing unique polypharmacological effects with potential clinical implications.

bioRxiv · Jan 14, 2019Pharmacology & Toxicology